NCT06058377 | S2206 | OPEN – Green Bay Oncology

Clinical Trial: NCT06058377 | S2206 | OPEN

NCT Number: NCT06058377

Protocol ID: S2206

Sponsor: OPEN

Disease Site: Breast-Early Stage

Disease Category: Breast

Detail: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.

For more details, click here.

Interested in participating in this trial?

Clinical Trial

First Name

Last Name

Phone

Preferred Contact Method:

Preferred Location:

Patient Type:

Current Patient New Patient

Interested in:

Cancer Clinical Trial Blood Disorder Clinical Trial

Disease Site:

Disease Category

What do all the numbers mean on clinical trials?

National Clinical Trial Identifier

The National Clinical Trial (NTC) is assigned by the National Library of Medicine when a new study appears in the clinical trials database.

ex: NCT0526225 | GY026 | NRG

PROTOCOL IDENTIFICATION NUMBER

Any unique identifier assigned to the protocol by the sponsor.

ex: NCT0526225 | GY026 | NRG

STUDY SPONSOR

A sponsor is an individual, institution, company or organization that takes the responsibility to initiate, manage and/or finance the clinical trial.

ex: NCT0526225 | GY026 | NRG